
Lantheus Holdings (LNTH) Stock Forecast & Price Target
Lantheus Holdings (LNTH) Analyst Ratings
Bulls say
Lantheus Holdings is a radiopharmaceutical-focused company with a promising future due to its strong product lineup and potential growth opportunities in the Alzheimer's diagnostic market. The company has a diversified revenue base with products in multiple categories, and it is expected to benefit from an increase in healthcare professionals' adoption of its products. The recent approval of TruVu and the upcoming PDUFA dates for two of its key products, LNTH-501 and MK6240, could further drive its growth. With the CEO transition on the horizon and potential contributions from royalty opportunities, Lantheus is positioned for success in the coming years.
Bears say
Lantheus Holdings is heavily reliant on two products, PYLARIFY and DEFINITY, for a majority of its revenue, making the company vulnerable to disruptions in either platform from competition or regulatory changes. Additionally, the company's dependence on external manufacturers and third-party payors for reimbursement creates further risks to the business. With PYLARIFY's launch of TruVu in 4Q26 expecting to secure new Transitional Pass Through (TPT) status in 2027, any delays or challenges in rolling out the new formulation could hinder future revenue growth and undermine the company's long-term growth plans.
This aggregate rating is based on analysts' research of Lantheus Holdings and is not a guaranteed prediction by Public.com or investment advice.
Lantheus Holdings (LNTH) Analyst Forecast & Price Prediction
Start investing in Lantheus Holdings (LNTH)
Order type
Buy in
Order amount
Est. shares
0 shares